EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: real-world outcomes of intensification and salvage strategies

Annalice Gandini iD, Federico Lipsich, Jeanne Netter-Coti, Widad Lahlou, Celine Lepere iD, Xavier Guerra, Olivier Pellerin, Julien Taieb iD, Tom Boeken, Claire Gallois iD

The Oncologist · 08.07.2026 · 31 (8)

DOI: 10.1093/oncolo/oyag214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 04.06.2026. Verfasst von Annalice Gandini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, 75015…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Salvage Therapy, Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatic arterial infusion chemotherapy (HAIC) is a valuable option in patients with liver-dominant metastatic colorectal cancer (mCRC) but remains underutilized due to limited data.

Methods

We conducted a retrospective study of mCRC patients treated with HAIC in an expert center between 2010 and 2024. Patients were grouped according to treatment setting: intensification (INT; 1st/2nd line) and salvage (SALV; ≥3rd line).

Results

Among 213 patients, 99 received INT-HAIC and 114 SALV-HAIC. SALV patients had worse baseline features, including more Eastern Cooperative Oncology Group performance status (ECOG PS ≥ 2; 16% vs 4%), RAS mutation (55% vs 45%), extra-hepatic disease (45% vs 23%), liver burden >50% (65% vs 40%), and prior intravenous (IV) oxaliplatin progression (41% vs 16%). Oxaliplatin was the main agent used (81% INT, 78% SALV). Objective response and disease control rate were 51%/77% (INT) and 32%/60% (SALV). Median progression-free survival (PFS), hepatic PFS, and overall survival were 7.6, 9, and 23 months (INT) and 3.7, 5.7, and 12 months (SALV). Prior IV oxaliplatin progression was associated with poorer outcomes of oxaliplatin-HAIC in the INT setting. Radical liver treatment followed HAIC in 28% (INT) and 7% (SALV). Grade 3–4 adverse events occurred in 42.7% and catheter complications in 26.7%. Concomitant antiangiogenic therapy was associated with a higher rate of catheter-related complications (44% vs 22%) and remained associated after adjustment for clinical covariates.

Conclusions

HAIC demonstrates promising efficacy and manageable toxicity in liver-dominant mCRC when delivered in expert multidisciplinary centers, although careful patient selection and caution with concomitant antiangiogenic therapy are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsSalvage TherapyLiver NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleInfusions, Intra-ArterialMaleMiddle AgedRetrospective StudiesHepatic ArteryAgedAdultOxaliplatin

Stichwörter der Autor:innen

hepatic arterial infusion chemotherapyintensification treatmentliver metastasesmetastatic colorectal cancersalvage therapy

Substanzen

Oxaliplatin

Autor:innen und Institutionen

  • Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, 75015, France.
  • SIRIC CARPEM Comprehensive Cancer Center, Paris-Cité University, Paris, 75006, France.
  • Department of Vascular and Oncological Interventional Radiology, Hôpital Européen Georges, Pompidou, Paris, 75015, France.
  • Université Paris Cité, Sorbonne Université, Inserm, Centre de Recherche des Cordeliers, F-75006 Paris, France.

ORCID-Profile: Annalice Gandini, Celine Lepere, Julien Taieb, Claire Gallois

Zitieren

APA

Gandini, A., Lipsich, F., Netter-Coti, J., Lahlou, W., Lepere, C., Guerra, X., Pellerin, O., Taieb, J., Boeken, T., & Gallois, C. (2026). Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: real-world outcomes of intensification and salvage strategies. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag214

Vancouver

Gandini A, Lipsich F, Netter-Coti J, Lahlou W, Lepere C, Guerra X, et al. Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: real-world outcomes of intensification and salvage strategies. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag214

BibTeX
@article{Gandini2026,
  author = {Gandini, Annalice and Lipsich, Federico and Netter-Coti, Jeanne and Lahlou, Widad and Lepere, Celine and Guerra, Xavier and Pellerin, Olivier and Taieb, Julien and Boeken, Tom and Gallois, Claire},
  title = {Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: real-world outcomes of intensification and salvage strategies},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {8},
  doi = {10.1093/oncolo/oyag214}
}
Kostenlos starten →